<DOC>
	<DOCNO>NCT00011037</DOCNO>
	<brief_summary>The purpose study test body 's immune system respond vaccine ALVAC-HIV vCP1452 determine vaccine safe give alone MN rgp120 . HIV infection AIDS cure , spite recent advance anti-HIV drug . Many worldwide population afford antiviral treatment infected people . HIV vaccine offer hope disease prevention . In trial , 2 experimental HIV vaccine call ALVAC vCP1452 MN rgp120 give volunteer Haiti , Brazil , Peru , Trinidad Tobago . The study determine volunteer ' immune system respond vaccine . ( This protocol change add new international site . )</brief_summary>
	<brief_title>ALVAC-HIV vCP1452 Alone Combined With MN rgp120</brief_title>
	<detailed_description>There cure HIV infection AIDS spite recent advance antiviral therapy . Furthermore , drug therapy expensive affected population . For reason , commitment development safe , effective vaccine prevent HIV infection AIDS worldwide . This study evaluate immunogenicity safety candidate HIV-1 vaccine , base canarypox vector term ALVAC , alone combine MN rgp120 product , 3 [ AS PER AMENDMENT 7/19/01 : 5 ] international site . [ AS PER AMENDMENT 7/19/01 : Volunteers Rio de Janeiro , Haiti , Trinidad Tobago comprise Part I ; volunteer Sao Paulo Peru comprise Part II . ] Volunteers Haiti , Brazil , [ AS PER AMENDMENT 7/19/01 : Peru ] Trinidad Tobago enrol 1 3 arm follow 18 month . Arm 1 volunteer receive ALVAC-HIV vCP1452 0 , 1 , 3 , 6 month . Arm 2 volunteer receive ALVAC-HIV vCP1452 schedule Arm 1 receive HIV-1 MN rgp120 subunit simultaneously 3-month 6-month vaccine dos . Arm 3 volunteer receive placebo . Blood urine sample collect immunologic assay , virologic determination , pregnancy testing , safety assessment . Risk behavior social harm assess every 6 month follow-up [ AS PER AMENDMENT 7/19/01 : Social harm assess every 3 month follow-up risk behavior every 6 month ] . At clinic visit volunteer receive counsel avoidance HIV infection pregnancy . Participants test HIV-1 every 3 [ AS PER AMENDMENT 7/19/01 : follow text delete : 6 ] month . Counseling follow-up need medical care provide .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Volunteers may eligible study : Are Brazil ( Rio de Janeiro ) , Haiti , Peru , Trinidad Tobago . Are 18 60 year old . Are HIVnegative . Have develop sexually transmit disease last 6 month . Have 2 sexual partner last 6 month . Have inject drug use crack cocaine last 6 month . Have exchange sex money drug last 6 month . Have use adequate birth control method 1 month prior study injection intend continue injection period ( 7 month ) . Are available 18 month followup . Have normal history physical examination . ( The criterion inclusion change original . ) Exclusion Criteria Volunteers eligible study : Have immune disease , chronic illness , cancer ( unless cure surgical removal ) , use medication affect immune system . Have medical mental condition , job interferes study requirement . Have sexual partner HIVinfected , unless practice abstinence always use condom last 6 month . Have sexual partner high risk HIV infection . Have receive live vaccine experimental agent within 30 day prior plan vaccination . Have receive blood product immunoglobulin past 6 month . Have active tuberculosis . Have severe allergic reaction , include 1 require hospitalization medical care , serious reaction vaccine . Have receive HIV1 vaccine placebo previous HIV vaccine trial . Are pregnant breastfeeding . Are allergic egg product , thimerosal , neomycin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HIV Antibodies</keyword>
	<keyword>HIV Antigens</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>CD4-Positive T-Lymphocytes</keyword>
	<keyword>CD8-Positive T-Lymphocytes</keyword>
	<keyword>Neutralization Tests</keyword>
	<keyword>Haiti</keyword>
	<keyword>Brazil</keyword>
	<keyword>Cytotoxicity , Immunologic</keyword>
	<keyword>Epitopes</keyword>
	<keyword>Viral Proteins</keyword>
	<keyword>Trinidad Tobago</keyword>
	<keyword>Peru</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>